- Home
- ACET vs SFWL Comparison
ACET vs SFWL Comparison
Compare ACET & SFWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACET
- SFWL
- Stock Information
- Founded
- ACET 1947
- SFWL 2001
- Country
- ACET United States
- SFWL China
- Employees
- ACET N/A
- SFWL N/A
- Industry
- ACET Biotechnology: Pharmaceutical Preparations
- SFWL Trucking Freight/Courier Services
- Sector
- ACET Health Care
- SFWL Industrials
- Exchange
- ACET Nasdaq
- SFWL Nasdaq
- Market Cap
- ACET 69.9M
- SFWL 82.3M
- IPO Year
- ACET N/A
- SFWL 2023
- Fundamental
- Price
- ACET $0.81
- SFWL $0.97
- Analyst Decision
- ACET Buy
- SFWL
- Analyst Count
- ACET 4
- SFWL 0
- Target Price
- ACET $5.50
- SFWL N/A
- AVG Volume (30 Days)
- ACET 1.7M
- SFWL 21.0K
- Earning Date
- ACET 11-05-2025
- SFWL 08-27-2025
- Dividend Yield
- ACET N/A
- SFWL N/A
- EPS Growth
- ACET N/A
- SFWL 31.68
- EPS
- ACET N/A
- SFWL 0.14
- Revenue
- ACET N/A
- SFWL $540,461,000.00
- Revenue This Year
- ACET N/A
- SFWL N/A
- Revenue Next Year
- ACET N/A
- SFWL N/A
- P/E Ratio
- ACET N/A
- SFWL $7.04
- Revenue Growth
- ACET N/A
- SFWL 21.10
- 52 Week Low
- ACET $0.45
- SFWL $0.86
- 52 Week High
- ACET $1.54
- SFWL $1.60
- Technical
- Relative Strength Index (RSI)
- ACET 49.83
- SFWL 36.31
- Support Level
- ACET $0.79
- SFWL $0.98
- Resistance Level
- ACET $1.03
- SFWL $1.20
- Average True Range (ATR)
- ACET 0.06
- SFWL 0.05
- MACD
- ACET 0.00
- SFWL -0.03
- Stochastic Oscillator
- ACET 18.11
- SFWL 4.17
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
About SFWL Shengfeng Development Limited
Shengfeng Development Ltd is a holding company. Through its subsidiaries, it offers contract logistics services in China. The contract logistics services offered by the company include planning and designing supply chains, designing facilities, processing orders, collecting payments, managing inventories, and providing client services.